Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 17;11(5):861–869. doi: 10.1080/19420862.2019.1612699

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 1. — Overall pre-existing reactivity to monoclonal human antibodies is often minimal. Pre-existing reactivity is expressed as Tier 2 (confirmatory) inhibition calculated from Tier 1 and Tier 2 signal from 60 normal human sera from treatment-naïve individuals obtained in the ACE-Bridge for a monoclonal, monospecific, fully human antibody directed against a soluble protein (mAb1). (a) The pattern of Tier 1 and Tier 2 signal (ECLU) for each normal human serum sample tested. (b) Tier 2 inhibition and frequency distribution show overall low mean Tier 2 inhibition, low biological variability and low 90th percentile of Tier 2 percent inhibition.